HDAC9 and Miyoshi myopathy: Combination therapy at an ACY-1215 dose of 160 mg daily was well tolerated, with less severe adverse effects compared with published data on non-selective HDAC inhibitors, suggesting that selective inhibition of HDAC6 is promising in MM treatment126.